Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.


Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?


Please Try Again {{ error }}

Send my password

An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Theratechnologies Inc. T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc is a specialty pharmaceutical company that addresses the unmet medical needs of HIV patients. It mainly operates in Canada and the United States. The company has two approved products, EGRIFTA marketed in Canada and the United States, and Trogarzo approved for commercialization in the United States.

The Power Play by The Market Herald
< Previous Video {{moreVideoText}} Next Video >

Stock Price Chart (TSX:TH)

Fundamentals Snapshot (TSX:TH)

Current News (TSX:TH)

Theratechnologies to Present Preliminary Safety and Efficacy Data from Phase 1 Trial of Sudocetaxel Zendusortide in Heavily Pretreated Cancer Patients at ASCO 2023

GlobeNewswire 3 days ago

Early Warning Report Issued Pursuant to National Instrument 62-103 - Acquisition of Securities of Theratechnologies Inc.

Canada NewsWire 9 days ago

Theratechnologies Reports on its Annual Meeting of Shareholders

GlobeNewswire May 9, 2023

Theratechnologies' Trogarzo® (Ibalizumab-uiyk) Shortens Time to HIV Undetectability and Extends Durability of Undetectability and Viral Suppression in a Matched Treatment Comparison

GlobeNewswire May 4, 2023

Theratechnologies Data Presentations at AACR 2023 Showcase Potential of Sudocetaxel Zendusortide as a Single Agent and in Combination with other Anticancer Therapies

GlobeNewswire April 18, 2023

Theratechnologies to Present at the 2023 Bloom Burton & Co. Healthcare Investor Conference

Newsfile April 18, 2023

Theratechnologies Reports Financial Results and Business Updates for First Quarter 2023

GlobeNewswire April 12, 2023

Theratechnologies to Announce First Quarter 2023 Financial Results and Provide Business Update

GlobeNewswire April 3, 2023

Theratechnologies to Present Preclinical Data at AACR Demonstrating Synergy Between TH1902 and Anti-PD-L1 Immunotherapy in Cold Tumor Model

GlobeNewswire March 14, 2023

Bullboard Posts (TSX:TH)

RE:RE:RE:RE:RE:RE:AACR Poster - very interesting

Great to to see these data come out. Bravo to our medical team and investigators. Paul Levesque  's short post on Linkendl ...
palinc2000 - 1 day ago

RE:RE:RE:RE:RE:AACR Poster - very interesting

I've thougth about that question too and knowing these things are always data driven, it seems to point to that. I've assumed...
Wino115 - 1 day ago

RE:RE:RE:RE:AACR Poster - very interesting

Just as an aside. They really should have developed their clinical grade Sortilin test to the point where it can be intergrated into the...
qwerty22 - 1 day ago

RE:RE:RE:AACR Poster - very interesting

So my take on their thought process (I'll be easily knocked from this with any new info) There is a serious lack of partial...
qwerty22 - 1 day ago

RE:RE:AACR Poster - very interesting

I don't know what's going on with this press release. It reads as a fairly incomplete part 2 with lots of enrollment still to...
qwerty22 - 1 day ago

RE:RE:RE:RE:RE:Interesting Context from Jones Research

It will be interesting to hear their restart plan. You could do something cheaply that's small and focused, maybe get somr UQAM money...
Wino115 - 2 days ago